Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Oncogenesis
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2018024231
pages 249-253

Ras Suppressor-1 (RSU-1) in Cancer Cell Metastasis: Friend or Foe?

Lefteris C. Zacharia
Department of Life and Health Sciences, School of Sciences and Engineering, University of Nicosia, Cyprus
Triantafyllos Stylianopoulos
Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus
Vasiliki Gkretsi
Biomedical Sciences Program, Department of Life Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus

SINOPSIS

Metastasis to distant organs and not the primary tumor itself is usually the cause of death for cancer patients. Hence, studying the key molecules and molecular pathways involved in metastasis are essential. Metastasis is a complex process in which cancer cells detach from the original tumor, migrate, and invade through surrounding tissues and metastasize to other sites of the body through the circulation. The cell-extracellular matrix (ECM) adhesion proteins play a fundamental role in this process as cancer cells need to weaken their adhesions to dissociate from the ECM as well as the neighboring cells within the tumor and finally form new adhesions and invade surrounding tissues. Ras suppressor-1 (RSU-1) was originally identified as a suppressor of Ras-dependent oncogenic transformation and found to be localized to cell-ECM adhesions where it binds to PINCH-1, a focal adhesion involved in cell survival. Although RSU-1 was connected to cancer early on, little is known about its expression in various cancer types or its role in metastasis. In this article, we review the recent literature regarding the expression of RSU-1 in various cancer types and its potential role in metastasis, discussing interesting findings and issues that still need to be addressed.


Articles with similar content:

Integrin Control of Tumor Invasion
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 4
Dara S. Missan , Michael DiPersio
Targeting Integrins in Cancer
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Chiara Pazzagli, Sandra Donnini
Endothelial Cells as Key Determinants of the Tumor Microenvironment: Interaction with Tumor Cells, Extracellular Matrix and Immune Killer Cells
Critical Reviews™ in Immunology, Vol.30, 2010, issue 6
Muhammad Zaeem Noman, Salem Chouaib, Claudine Kieda, Fathia Mami-Chouaib, Houssem Benlalam, Curzio Ruegg
IAPs: Mediators of Oncogenesis and Targets for Anticancer Therapy
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 5-6
Ali Bettaieb, Stéphanie Plenchette, Laurence Dubrez, Sarra Bouaouiche
Drugs That Target Gene Expression: An Overview
Critical Reviews™ in Eukaryotic Gene Expression, Vol.6, 1996, issue 1
Filippo Cavalieri